Novartis completes FDA application for 'cancer-killing' technology

Cara Livernois | | Health Exec | Precision Medicine

The race to produce the first CAR-T, a technology capable of reprograming a cancer patient's white blood cells to kill tumor cells, has reached its next phase, thanks to Novartis. In Forbes, Samuele Butera, the Global Business Leader for Cell & Gene Therapies at Novartis, explains the company’s work in fighting cancer within the body.

After announcing the company had completed the application for the use of CAR-T in children with acute lymphoblastic leukemia, the company is currently waiting for a response from the Food and Drug Administration. Novartis’ application comes before that from Kite Pharmaceuticals, who announced its intention to apply in Dec. 2016.

Read the full story by clicking below: 

Novartis Makes Plans For Its Cancer-Killing T Cells

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.